Taizhou Four Dimensional Chemical Factory

Main research purpose: According to the relevant provisions of bioequivalence test, oxcarbazepine tablets (trade name: Trilepine; specification: 0.3g) with Novartis Pharma Schweiz AG as the licensee were selected as the reference preparation, and the test preparation oxcarbazepine tablets (specification: 0.3g) produced by Zhejiang Siwei Pharmaceutical Technology Co., Ltd. were subjected to postprandial human bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation oxcarbazepine tablets (specification: 0.3g) and the reference preparation oxcarbazepine tablets (trade name: Trilepine; specification: 0.3g) by healthy volunteers.

Main research purpose: According to the relevant provisions of bioequivalence test, oxcarbazepine tablets (trade name: Trileptin; specification: 0.3g) with Novartis Pharma Schweiz AG as the licensee were selected as the reference preparation, and the test preparation oxcarbazepine tablets (specification: 0.3g) produced by Zhejiang Siwei Pharmaceutical Technology Co., Ltd. were subjected to fasting human bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under fasting conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation oxcarbazepine tablets (specification: 0.3g) and the reference preparation oxcarbazepine tablets (trade name: Trileptin; specification: 0.3g) by healthy volunteers.

Main research purpose: According to the relevant provisions of bioequivalence test, dapagliflozin metformin sustained-release tablets (Ⅰ) (trade name: Anda Shi® (XIGDUO XR®), specification: 10mg/1000mg) with AstraZeneca AB as the licensee was selected as the reference preparation, and the test preparation dapagliflozin metformin sustained-release tablets (Ⅰ) (specification: 10mg/1000mg) produced and provided by Zhejiang Siwei Pharmaceutical Technology Co., Ltd. was subjected to human bioequivalence test under fasting and postprandial administration conditions, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study objective: To observe the safety of oral administration of the test preparation dapagliflozin metformin sustained-release tablets (I) (specification: 10 mg/1000 mg) and the reference preparation dapagliflozin metformin sustained-release tablets (I) (trade name: Anda-release® (XIGDUO XR®), specification: 10 mg/1000 mg) to healthy subjects.